Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Open access

 

Navigating the global pharma order in 2026 —in conversation with ING’s Stephen Farrelly and Diederik Stadig

Ahead of the HBI 2026 session ‘The new global pharma order: Trump, China and Europe's uncertain future’, HBI spoke to Stephen Farrelly, Managing Director, Global Lead Healthcare & Pharma at ING and Diederik Stadig, Senior Economist, Healthcare & Pharma at ING on what the future holds for pharma investment and strategy, from regulatory risks and European biopharma's structural challenges to the evolving role of CDMOs, CROs, and the role of private equity.
March 18, 2026

What Europe can learn from Asia’s high-volume ophthalmology models — in conversation with Carl Zeiss Meditec

Ahead of the Ophthalmology Community Summit at HBI 2026 in partnership with Carl Zeiss Meditec, HBI speaks to Ana Neves, Head of Global Strategic Marketing, and Michael Achtelik, Managing Director of Carl Zeiss Meditec about how digital workflows, interoperability and AI are influencing the development of ophthalmic care, and what Europe may be able to learn from developments in Asia, and vice versa.
March 12, 2026

Interview: George Tomeski, Helfie AI

Helfie AI is an Australian start-up that is building what its founder, George Tomeski, describes as “a whole new operating system for human health”. This is not simply hyperbole or PR-speak. What Helfie is building is indeed groundbreaking.
January 7, 2026

FREE BLOG The HBI Hot Private Equity List— coming January 2026

In January 2026, HBI will publish its first-ever Hot Private Equity Firms List, spotlighting the investors most active in healthcare deals globally. Built from publicly available portfolio disclosures and announced transactions, the list identifies the private equity firms deploying capital across healthcare services, life sciences, medtech and digital health. Rather than a simple ranking, the […]
December 18, 2025

FREE BLOG Could European drug prices increase following Trump’s pharma policy? 

Earlier this month, The Trump administration launched TrumpRx.gov, a government website that allows consumers to purchase prescription drugs directly. The move is part of a broader overhaul of US pharmaceutical policy, which includes letters sent to 17 drugmakers demanding lower domestic prices and the enforcement of the Most Favoured Nation (MFN) (lowering US drug prices to those in other developed countries).
October 23, 2025

Amethyst enters Portugal

Pan-European oncology group Amethyst has entered the Portuguese market. It has acquired Júlio Teixeira, a private Portuguese oncology provider consisting of two clinics.
October 9, 2025
Older posts
Newer posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us